By Counterforce Health Team in Dojolvi (triheptanoin) —

Getting Dojolvi (Triheptanoin) Covered by Aetna CVS Health in Ohio: Coding, Appeals, and External Review Guide

Quick Answer: Getting Dojolvi Covered by Aetna CVS Health in Ohio

Dojolvi (triheptanoin) requires prior authorization through Aetna CVS Health with molecular confirmation of long-chain fatty acid oxidation disorders (LC-FAOD). Submit PA via Availity portal using ICD-10 code E71.310, HCPCS J8499, and valid NDC numbers. If denied, Ohio residents have 180 days for internal appeals, then external review through Independent Review Organizations. Start today: Gather genetic testing results, calculate dosing based on daily caloric intake, and document any MCT product discontinuation.

Table of Contents

  1. Coding Basics: Medical vs. Pharmacy Benefit
  2. ICD-10 Mapping for LC-FAOD
  3. Product Coding: HCPCS, NDC, and Units
  4. Clean Prior Authorization Anatomy
  5. Common Coding Pitfalls
  6. Aetna CVS Health Verification
  7. Appeals Process in Ohio
  8. Pre-Submission Audit Checklist

Coding Basics: Medical vs. Pharmacy Benefit Paths

Dojolvi typically falls under the pharmacy benefit for home administration, requiring prior authorization through CVS Caremark. The medication is distributed via CVS Specialty Pharmacy and requires molecular confirmation of LC-FAOD.

Coverage Requirements at a Glance

Requirement What It Means Where to Find It
PA Required Yes, through CVS Caremark CVS Specialty Drug List
Formulary Status Non-formulary specialty Aetna formulary lookup
Step Therapy May require MCT trial documentation Payer-specific policies
Site of Care Home administration FDA labeling
Age Limits Adults and children FDA Access Data

ICD-10 Mapping for LC-FAOD

The primary diagnosis code for Dojolvi coverage is E71.310 (Long chain/very long chain acyl CoA dehydrogenase deficiency). This billable code falls under the broader category E71.31 (Disorders of fatty-acid oxidation).

Relevant ICD-10 Hierarchy

  • E71.3: Disorders of fatty-acid metabolism
    • E71.31: Disorders of fatty-acid oxidation
      • E71.310: Long chain/very long chain acyl CoA dehydrogenase deficiency
      • E71.314: Muscle carnitine palmitoyltransferase deficiency
      • E71.318: Other disorders of fatty-acid oxidation

Documentation Requirements

For E71.310 coding, include:

  • Molecular confirmation via genetic testing (e.g., ACADVL gene mutations)
  • Biochemical evidence such as elevated C14:1 acylcarnitine levels
  • Clinical manifestations like rhabdomyolysis or hypoglycemia episodes
  • Newborn screening results if applicable
Clinician Corner: Document the specific LC-FAOD subtype in your notes. For example, "VLCAD deficiency confirmed by biallelic pathogenic variants in ACADVL gene" strengthens the case for E71.310 over the broader E71.318 code.

Product Coding: HCPCS, NDC, and Units

HCPCS/J-Code Information

Dojolvi lacks a specific permanent HCPCS J-code. Use J8499 (Prescription drug, oral, non-chemotherapeutic, NOS) for billing purposes.

NDC Numbers and Units

  • Primary billing unit: Milliliters (mL)
  • Caloric content: 8.3 kcal per mL
  • NDC numbers: Use valid manufacturer NDCs from Ultragenyx (verify current numbers with wholesaler)

Dosing Calculation Formula

Total Daily Dose (mL) = (Daily Caloric Intake × Target % DCI) ÷ 8.3 kcal/mL

Example calculation:

  • Patient's DCI: 2,000 kcal/day
  • Target dose: 25% of DCI
  • Calculation: (2,000 × 0.25) ÷ 8.3 = 60.2 mL/day (round to 60 mL)
  • Divided into 4 doses: 15 mL per dose

Use the official dosing calculator for precise calculations.

Clean Prior Authorization Anatomy

Required Documentation Checklist

Clinical Information:

  • Confirmed LC-FAOD diagnosis with genetic testing results
  • ICD-10 code E71.310 or appropriate variant
  • Patient's calculated daily caloric intake
  • Proposed dosing schedule (≤35% DCI, ≥4 doses daily)
  • Documentation of MCT product discontinuation

Prescriber Requirements:

  • Board-certified metabolic specialist or geneticist
  • Attestation of medical necessity
  • Monitoring plan for safety and efficacy

Prior Authorization Submission: Submit via Availity portal at least two weeks before treatment initiation.

Common Coding Pitfalls

Frequent Errors to Avoid

  1. Unit Conversion Mistakes: Always calculate in mL, not grams
  2. Concurrent MCT Products: Document discontinuation of all other MCT supplements
  3. Inadequate Genetic Documentation: Include complete molecular testing results
  4. Wrong Specialist: Ensure prescriber is qualified (metabolic specialist/geneticist)
  5. Dosing Errors: Verify calculations using official tools

Billing Best Practices

  • Use J8499 with valid NDC numbers
  • Include daily mL dosing in quantity calculations
  • Attach genetic testing reports to PA submissions
  • Document clinical rationale for dosing percentage

Aetna CVS Health Verification

Pre-Submission Verification Steps

  1. Check formulary status via Aetna provider portal
  2. Confirm PA requirements through CVS Caremark
  3. Verify specialty pharmacy distribution requirements
  4. Review current precertification list (updated March 1, 2026)

Contact CVS Specialty at 1-800-237-2767 for distribution confirmation.

Appeals Process in Ohio

If your Dojolvi prior authorization is denied by Aetna CVS Health, Ohio residents have specific rights and timelines for appeals.

Internal Appeals Process

Level 1 Appeal:

  • Timeline: File within 180 days of denial notice
  • Decision time: 30 days for pre-authorization, 60 days post-service
  • Submission: Via Availity portal or certified mail

Level 2 Appeal:

  • Timeline: File within 60 days of Level 1 denial
  • Decision time: Same as Level 1
  • Requirements: Include additional clinical evidence

External Review in Ohio

After exhausting internal appeals, Ohio residents can request external review through an Independent Review Organization (IRO).

Key Requirements:

  • File within 180 days of final internal denial
  • Submit request to Aetna, who forwards to assigned IRO
  • Financial responsibility must exceed $500

Timelines:

  • Standard review: 30 days from request
  • Expedited review: 72 hours (requires physician certification of urgency)

Filing Process:

  1. Complete Aetna's Request for External Review Form
  2. Include final denial letter and supporting documentation
  3. Submit additional clinical information within 10 business days if requested

For assistance, contact the Ohio Department of Insurance Consumer Services Division at 1-800-686-1526.

From Our Advocates: We've seen LC-FAOD cases succeed on external review when the initial denial cited "experimental" status. The key was submitting FDA approval documentation and peer-reviewed evidence showing Dojolvi as the only FDA-approved therapy for LC-FAOD, along with detailed genetic testing confirming the specific enzyme deficiency.

Pre-Submission Audit Checklist

Before submitting your Dojolvi prior authorization:

Clinical Documentation:

  • Genetic testing results confirming LC-FAOD
  • Correct ICD-10 code (E71.310 or appropriate)
  • Calculated daily caloric intake and dosing
  • MCT discontinuation documented
  • Prescriber qualifications verified

Coding Verification:

  • HCPCS J8499 selected
  • Valid NDC numbers confirmed
  • Units calculated in mL
  • Quantity limits checked

Submission Requirements:

  • PA form completed via Availity
  • All supporting documents attached
  • Submission at least 2 weeks before needed
  • Confirmation receipt obtained

Frequently Asked Questions

How long does Aetna CVS Health prior authorization take for Dojolvi? Standard PA decisions typically take 30-45 days. For urgent cases, request expedited review for decisions within 72 hours.

What if Dojolvi is non-formulary on my plan? Submit a formulary exception request with your PA, including clinical rationale and evidence that Dojolvi is the only FDA-approved therapy for LC-FAOD.

Can I request an expedited appeal in Ohio? Yes, if a physician certifies that delay would seriously endanger your health, both internal and external appeals can be expedited to 72-hour decisions.

Does step therapy apply if I've never tried MCT products? Aetna may require documentation of MCT product trials or contraindications. Include clinical rationale for why Dojolvi is first-line appropriate.

What happens after external review in Ohio? IRO decisions are binding on Aetna. If approved, coverage must be provided. If denied, you retain rights to legal action or regulatory complaints.

Cost Savings and Support Options

Manufacturer Support:

  • Patient assistance programs through Ultragenyx
  • Copay assistance for eligible commercially insured patients
  • Dojolvi patient support resources

Foundation Grants:

  • National Organization for Rare Disorders (NORD)
  • Patient Advocate Foundation copay relief programs
  • Disease-specific foundations for metabolic disorders

When to Escalate

Contact the Ohio Department of Insurance if:

  • Aetna improperly denies external review eligibility
  • Appeal deadlines are not met by the insurer
  • You need assistance navigating the process

Ohio DOI Contact:

For complex cases requiring targeted appeals with evidence-backed arguments, Counterforce Health helps patients and clinicians turn insurance denials into successful approvals by analyzing denial letters, plan policies, and clinical notes to draft point-by-point rebuttals aligned with payer requirements.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions vary by plan and individual circumstances. Always consult with your healthcare provider and insurance plan for specific guidance. For official Ohio insurance regulations and appeal procedures, refer to the Ohio Department of Insurance website.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.